Our Recommendations
- Déclaration sur l’efficacité du vaccin COVID-19 d’AstraZeneca (ChAdOx1 nCoV-19) contre les variants du SARS-CoV-2 (2021)
- Guidance for surveillance of SARS-CoV-2 variants: Interim guidance, 9 August 2021 (2021)
- Variants (2021)
- COVID Reference 2021.6 EN (2021)
- Statement on the Efficacy of the AstraZeneca COVID-19 Vaccine (ChAdOx1 nCoV-19) against the SARS-CoV-2 Variants (2021)
New Publications
- Update 80: What we know about new COVID-19 Variants of Concern - the latest on the global situation & Omicron BA.4/5 (2022)
- Special Focus: Update on SARS-CoV-2 Variants of Interest and Variants of Concern (2022)
- Emerging SARS-CoV-2 Variants (2021)
- Standard Operating Procedure for Epidemiological Surveillance & Response for the new variant of SARS-CoV-2 in the context of regulated resumption of limited flights originating from United Kingdom (UK (2021)
- WHO Science in 5 Episode #20 - COVID-19 - Variants & Vaccines (2021)
Filter
37
Featured
Recommendations
8
Language
Document type
Fact sheets
17
Guidelines
6
Videos
6
Studies & Reports
3
Training Material
2
Resource Platforms
2
Manuals
1
Countries / Regions
Russia
3
Niger
2
Germany
2
West and Central Africa
2
France
2
Spain
2
East and Southern Africa
2
South Africa
2
Brazil
2
Mali
2
South Sudan
2
Colombia
1
Mexico
1
El Salvador
1
Turkey
1
Benin
1
Kazakhstan
1
Chile
1
Cameroon
1
Syria
1
Senegal
1
Congo-Brazzaville
1
Burkina Faso
1
Peru
1
Morocco
1
Qatar
1
Mauritania
1
Mozambique
1
Haiti
1
Dominican Republic
1
Venezuela
1
Latin America and the Carribbean
1
Jordan
1
Saudi Arabia
1
Congo, Democratic Republic of
1
Middle East and North Africa
1
Tunisia
1
United Kingdom
1
Portugal
1
Belarus
1
Israel
1
Southern Africa
1
Côte d’Ivoire / Ivory Coast
1
Bolivia
1
Argentina
1
Lebanon
1
Vietnam
1
Eastern Europe
1
Nicaragua
1
Egypt
1
Sudan
1
Yemen
1
Honduras
1
Chad
1
Libya
1
Iraq
1
Somalia
1
Ecuador
1
India
1
Madagascar
1
Cuba
1
Guatemala
1
Authors & Publishers
Publication Years
Category
COVID-19
14
Guidelines
1
Toolboxes
SARS-CoV-2 Variants
37
Surveillance & Contact tracing
5
Video & Audio
3
Country specific documents
3
Videos
3
Training, others
2
Communication Material
2
Vaxzevria (Astra Zeneca)
2
Clinical Guidelines
1
Prevention & Preparedness
1
Clinical Aspects
1
Public Health
1
Diagnostics & Laboratory Guidance
1
Scientific & Research Studies
1
Information for the Public
1
Vaccine Candidates & Research
1
Immunization Guidelines
1
Non-pharmaceutical interventions (NPIs)
1
Logistics & Supply
1
COVAX Initiative
1
Research & Pipeline
1
doi: https://doi.org/10.1101/2020.10.28.20221143
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
How concerned should we be about the new variants of SARS CoV 2 which cause COVID-19? Is it unusual for viruses to change and mutate? Do vaccines protect against these variants and what can you do to protect yourself? WHO’s Chief Scientist Dr Soumya Swaminathan explains in Science in 5
Updated 28 January 2020
Variants
recommended
updated regularly
Available in English, French, Chinese, Arabic, Russian
8 February 2021
On the 9 February 2021, Africa CDC convened a special session of the Africa Task Force for COVID-19 to review existing data and evidence and recommend
On the 9 February 2021, Africa CDC convened a special session of the Africa Task Force for COVID-19 to review existing data and evidence and recommend
Вариант вируса, названный «SARSCoV-2, вариант202012/01»,впервые был выявлен в Соединенном Королевстве, и сейчас его циркуляция подтверждена в ряде стран Европейского ре...
1 March 2021
This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
The NY Times variant tracker is perhaps the most accessible and relevant publication for non-molecular biologists and the general public
Each coronavirus contains nearly 30,000 letters of RNA. This genetic information allows the virus to infect cells and hijack them to make new viruses.
n light of the potential risk posed by SARS-CoV-2 variants, in January 2021 WHO organized an ad hoc consultation to discuss the development of an R&D agenda in response to existing and emerging SARS-CoV-2 variants.
The key objectives were to identify the critical research questions related to var...
21 Dec 2021. Slideset updated regularly to include the latest data and guidance on COVID-19 vaccines, including implications of emerging SARS-CoV-2 variants
What do we know about the Delta variant so far? How can we assess our risk? What strategies should we apply to protect ourselves whether we are in a low vaccination or high vaccination setting? WHO’s Dr Maria Van Kerkhove explains in Science in 5.
